What Is Multifocal Motor Neuropathy? Multifocal motor neuropathy (MMN) is a rare disease that causes slowly worsening muscle weakness, mainly in your hands, arms, and legs. It affects your body's ...
June 27, 2012 — Immune Globulin Infusion (Human), 10% (Gammagard Liquid, Baxter International, Inc), has been approved by the US Food and Drug Administration (FDA) as a treatment for multifocal motor ...
Multifocal motor neuropathy (MMN) is a rare inflammatory neuropathy characterized by slowly progressive, asymmetric distal limb weakness without sensory loss. The clinical presentation of MMN may ...
"Multifocal Motor Neuropathy Pipeline Insight"DelveInsight's analysis reveals several companies advancing innovative therapies in the multifocal motor neuropathy clinical pipeline, with groundbreaking ...
Baxter International announced that it has submitted a supplemental Biologics License Application (sBLA) for Gammagard Liquid 10% [immune globulin infusion (human)] for the treatment of multifocal ...
Identification and correct diagnosis of the chronic acquired demyelinating polyneuropathies is important because they are immune-mediated and, therefore, amenable to treatment Early diagnosis and ...
Baxter International Inc. (NYSE:BAX) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID 10% [Immune Globulin Infusion (Human)] as a treatment for multifocal ...
Baxter International Inc. (NYSE:BAX) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion for extension ...
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
Amsterdam, the Netherlands—June 20, 2023—argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results